Last reviewed · How we verify

Pneumococcal Acute Otitis Media — Treatment Landscape & Competitive Intelligence

Pneumococcal Acute Otitis Media (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pneumococcal Acute Otitis Media, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Zithromax azithromycin Pfizer Inc. Macrolide antibiotic (azalide) Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor 1991-11-01
Cefzil cefprozil Teva Pharmaceuticals USA Cephalosporin Antibacterial [EPC] 1991-01-01
Augmentin 250 CLAVULANIC ACID Dr Reddys Labs Inc beta Lactamase Inhibitor 1984-01-01
Amoxil amoxicillin Generic (originally Beecham/GSK) Aminopenicillin (Beta-lactam antibiotic) 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C 1972-01-01
Azo Gantrisin sulfafurazole Alra Sulfonamide Antimicrobial Endothelin-1 receptor 1971-01-01
Unasyn AMPICILLIN Bristol-Myers Squibb Penicillin-class Antibacterial Transient receptor potential cation channel subfamily M member 4 1965-01-01
Benzamycin Erythromycin Lactobionate Pfizer Macrolide Potassium voltage-gated channel subfamily H member 2 1964-01-01
E-Mycin erythromycin Generic (originally Abbott/Lilly) Macrolide [EPC] Aldehyde oxidase, Bile salt export pump, Cytochrome P450 1B1 1952-01-01
Penicillin G Potassium In Plastic Container Benzylpenicillin Pfizer Penicillin-class Antibacterial 1947-01-01
Phenoxymethylpenicillin Phenoxymethylpenicillin Katarina Hedin Bacterial penicillin-binding protein, Penicillin-binding protein 1A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 2 drugs in Pneumococcal Acute Otitis Media
  2. Alra · 1 drug in Pneumococcal Acute Otitis Media
  3. Bristol-Myers Squibb · 1 drug in Pneumococcal Acute Otitis Media
  4. Dr Reddys Labs Inc · 1 drug in Pneumococcal Acute Otitis Media
  5. Generic (originally Abbott/Lilly) · 1 drug in Pneumococcal Acute Otitis Media
  6. Generic (originally Beecham/GSK) · 1 drug in Pneumococcal Acute Otitis Media
  7. Karlstad University · 1 drug in Pneumococcal Acute Otitis Media
  8. Katarina Hedin · 1 drug in Pneumococcal Acute Otitis Media
  9. King George's Medical University · 1 drug in Pneumococcal Acute Otitis Media
  10. Pfizer Inc. · 1 drug in Pneumococcal Acute Otitis Media
  11. Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. · 1 drug in Pneumococcal Acute Otitis Media
  12. · 1 drug in Pneumococcal Acute Otitis Media

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pneumococcal Acute Otitis Media:

Cite this brief

Drug Landscape (2026). Pneumococcal Acute Otitis Media — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pneumococcal-acute-otitis-media. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing